Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Newleos Therapeutics, Inc.

News headline image
Newleos Names Rohan Palekar as Board Chairman
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Announces Dosing of First Participant in Phase 1b Study of NTX-2001 for Alcohol Use Disorder
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Announces Dosing of First Participant in U.K. Phase 1b Study of NTX-1955 in Generalized Anxiety Disorder
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics Appoints Timothy Noyes as President and Chief Executive Officer
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit
From Newleos Therapeutics, Inc.
Via Business Wire
Tickers GS
News headline image
Newleos Therapeutics Announces Clinical Progress Across Neuropsychiatric Pipeline
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics Announces Poster Presentation to be Featured at the 2025 World Congress of Biological Psychiatry
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics Appoints Stephen Brannan to Board of Directors and Announces NTX-1955 Clinical Progress in Generalized Anxiety Disorder
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics Announces Clinical Advisory Board to Support Key Neuropsychiatry Programs
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics Expands Leadership Team to Advance its Clinical-Stage Neuropsychiatric Programs and Drive Corporate Growth
From Newleos Therapeutics, Inc.
Via Business Wire
News headline image
Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines
From Newleos Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback